The disclosure relates to integrin binding peptides, pharmaceutical compositions comprising the peptides and to uses thereof as therapeutic, diagnostic, imaging and targeting agents.

A process for the extraction of collagen from collagen-containing matter, wherein the process comprises; incubating the collagen-containing matter in an acidic solution to form an incubant, then diafiltrating the incubant to substantially purify solubilised collagen within the incubant, thereby forming a retentate, then separating the soluble and insoluble matter of the retentate to remove the remaining insoluble matter, wherein the soluble matter is a substantially pure collagen solution.

A process for the extraction of collagen from collagen-containing matter, wherein the process comprises; incubating the collagen-containing matter in an acidic solution to form an incubant, then diafiltrating the incubant to substantially purify solubilised collagen within the incubant, thereby forming a retentate, then separating the soluble and insoluble matter of the retentate to remove the remaining insoluble matter, wherein the soluble matter is a substantially pure collagen solution.

Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.

Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.

The present invention provides novels method of targeting delivery of a compound to hypoxic cells, for example treatment of diseases and disorders associated with hypoxia, comprising administration of a construct comprising a targeting carrier peptide and a compound for delivery to a hypoxic cell. The invention also provides novel methods for the treatment of diseases or disorders of the eye by administration of a novel construct, a nucleic acid encoding a novel construct, and/or a nucleic acid vector comprising a nucleic acid encoding a novel construct. The invention further provides novel constructs, nucleic acids encoding such constructs, and/or nucleic acid vectors comprising nucleic acids encoding such constructs.

There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing renal failure; renal dysfunction; respiratory failure; respiratory dysfunction; or acute lung injury. Provided herein are uses, pharmaceutical compositions, and commercial packages associated therewith.

There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing renal failure; renal dysfunction; respiratory failure; respiratory dysfunction; or acute lung injury. Provided herein are uses, pharmaceutical compositions, and commercial packages associated therewith.

The present invention provides a method of producing a modified collagen, including the steps of: providing a collagen comprising a S—S bond; introducing a —SH group in said collagen comprising a S—S bond by reduction of the S—S bond to provide a collagen thiol comprising a —SH group; and nitrosating the —SH group of the collagen thiol to provide a modified collagen, said modified collagen comprising S-nitroso groups.

The present invention provides a method of producing a modified collagen, including the steps of: providing a collagen comprising a S—S bond; introducing a —SH group in said collagen comprising a S—S bond by reduction of the S—S bond to provide a collagen thiol comprising a —SH group; and nitrosating the —SH group of the collagen thiol to provide a modified collagen, said modified collagen comprising S-nitroso groups.